Arcturus reverse merges into the market, steering RNA projects to the clinic
Israel’s Alcobra started out 2017 with a disaster, forced to concede that their Phase III study of MDX — its only drug in the clinic …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
